Skip to main content Accessibility help

Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies

  • Joseph Kambeitz (a1), Anissa Abi-Dargham (a2), Shitij Kapur (a1) and Oliver D. Howes (a3)



The hypothesis that cortical dopaminergic alterations underlie aspects of schizophrenia has been highly influential.


To bring together and evaluate the imaging evidence for dopaminergic alterations in cortical and other extrastriatal regions in schizophrenia.


Electronic databases were searched for in vivo molecular studies of extrastriatal dopaminergic function in schizophrenia. Twenty-three studies (278 patients and 265 controls) were identified. Clinicodemographic and imaging variables were extracted and effect sizes determined for the dopaminergic measures. There were sufficient data to permit meta-analyses for the temporal cortex, thalamus and substantia nigra but not for other regions.


The meta-analysis of dopamine D2/D3 receptor availability found summary effect sizes of d =–0.32 (95% CI −0.68 to 0.03) for the thalamus, d =–0.23 (95% CI −0.54 to 0.07) for the temporal cortex and d = 0.04 (95% CI −0.92 to 0.99) for the substantia nigra. Confidence intervals were wide and all included no difference between groups. Evidence for other measures/regions is limited because of the small number of studies and in some instances inconsistent findings, although significant differences were reported for D2/D3 receptors in the cingulate and uncus, for D1 receptors in the prefrontal cortex and for dopamine transporter availability in the thalamus.


There is a relative paucity of direct evidence for cortical dopaminergic alterations in schizophrenia, and findings are inconclusive. This is surprising given the wide influence of the hypothesis. Large, well-controlled studies in drug-naive patients are warranted to definitively test this hypothesis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies
      Available formats


Corresponding author

Oliver D. Howes, BM, BCh, MA, MRCPsych, PhD, DM, Department of Psychosis Studies, Institute of Psychiatry, King's College London, PO Box 67, Camberwell, London SE5 8AF, UK. Email:


Hide All

Declaration of interest

O.D.H has consulted for and/or spoken at events organised by AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, Roche and Sunovion. A.A.-D. has consulted or given lectures for Sunovion, Shire, and Bristol-Myers Squibb/Otsuka. S.K. has received grant support from AstraZeneca and GlaxoSmithKline and has served as consultant and/or speaker for AstraZeneca, Bioline, Bristol-Myers Squibb/Otsuka, Eli Lilly, Janssen (Johnson & Johnson), Lundbeck, Neuro-Search, Pfizer, Roche, Servier, and Solvay/Wyeth.



Hide All
1 American Psychiatric Association. APATF on Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Publishing, 2000.
2 Lopez, AD. Global Burden of Disease and Risk Factors. Oxford University Press, 2006.
3 McGuire, P, Howes, OD, Stone, J, Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci 2008; 29: 91–8.
4 Lewis, DA, Gonzalez-Burgos, G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016–22.
5 Meltzer, HY, Stahl, SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976; 2: 1976.
6 Van Rossum, JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492–4.
7 Davis, KL, Kahn, RS, Ko, G, Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–86.
8 Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 2009; 35: 549–62.
9 Howes, OD, Kambeitz, J, Kim, E, Stahl, D, Slifstein, M, Abi-Dargham, A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776–86.
10 Abi-Dargham, A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004; 7 (suppl 1): S15.
11 Wong, DF, Wagner, HN Jr, Tune, LE, Dannals, RF, Pearlson, GD, Links, JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–63.
12 Farde, L, Halldin, C, Stone-Elander, S, Sedvall, G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 1987; 92: 278–84.
13 Reith, J, Benkelfat, C, Sherwin, A, Yasuhara, Y, Kuwabara, H, Andermann, F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651–4.
14 Halldin, C, Farde, L, Högberg, T, Mohell, N, Hall, H, Suhara, T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36: 1275–81.
15 Mukherjee, J, Yang, ZY, Brown, T, Lew, R, Wernick, M, Ouyang, X, et al. Preliminary ass essment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 1999; 26: 519–27.
16 Kessler, RM, Mason, NS, Votaw, JR, De Paulis, T, Clanton, JA, Ansari, MS, et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 1992; 223: 105–7.
17 Martin, GE, Williams, M, Pettibone, DJ, Zrada, MM, Lotti, VJ, Taylor, DA, et al. Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo. J Pharmacol Exp Ther 1985; 233: 395401.
18 Elsinga, PH, Hatano, K, Ishiwata, K. PET tracers for imaging of the dopaminergic system. Curr Med Chem 2006; 13: 2139–53.
19 Sedvall, G, Pauli, S, Karlsson, P, Farde, L, Nordström, AL, Nyberg, S, et al. PET imaging of neuroreceptors in schizophrenia. Eur Neuropsychopharmacol 1995; 5 (suppl): 2530.
20 Farde, L, Wiesel, FA, Halldin, C, Sedvall, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71–6.
21 Abi-Dargham, A, Xu, X, Thompson, JL, Gil, R, Kegeles, LS, Urban, N, et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. J Psychopharmacol (Oxford) 2012; 26: 794805.
22 Ioannidis, J, Lau, J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001; 98: 831–6.
23 The R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2010.
24 Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 148.
25 Champely, S. pwr: Basic Functions for Power Analysis. R Package Version 1.1.1. R Project, 2009 (
26 Hedges, LV, Olkin, I. Statistical Methods for Meta-Analysis. Academic Press, 1985.
27 Hedges, LV, Vevea, JL. Fixed-and random-effects models in meta-analysis. Psychol Methods 1998; 3: 486.
28 Raudenbusch, S. Analysing effect sizes: random effects models. In The Handbook of Research Synthesis and Meta-Analysis (2nd edn) (eds Cooper, H, Hedges, LV, Valentine, JC): 295315. Russell Sage Foundation, 2009.
29 Higgins, J, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557.
30 Higgings, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Cochrane Collaboration, 2011 (
31 Egger, M, Smith, GD, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629.
32 Innis, RB, Cunningham, VJ, Delforge, J, Fujita, M, Gjedde, A, Gunn, RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533–9.
33 Buchsbaum, MS, Christian, BT, Lehrer, DS, Narayanan, TK, Shi, B, Mantil, J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85: 232–44.
34 Lehrer, DS, Christian, BT, Kirbas, C, Chiang, M, Sidhu, S, Short, H, et al. 18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res 2010; 122: 4352.
35 Yasuno, F, Suhara, T, Okubo, Y, Sudo, Y, Inoue, M, Ichimiya, T, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004; 161: 1016–22.
36 Yasuno, F, Suhara, T, Okubo, Y, Ichimiya, T, Takano, A, Sudo, Y, et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia. Psychiatry Res 2005; 138: 197207.
37 Suhara, T, Okubo, Y, Yasuno, F, Sudo, Y, Inoue, M, Ichimiya, T, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002; 59: 2530.
38 Talvik, M, Nordström, A-L, Olsson, H, Halldin, C, Farde, L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003; 6: 361–70.
39 Talvik, M, Nordström, A-L, Okubo, Y, Olsson, H, Borg, J, Halldin, C, et al. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 2006; 148: 165–73.
40 Kegeles, LS, Slifstein, M, Xu, X, Urban, N, Thompson, JL, Moadel, T, et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 2010; 68: 634–41.
41 Glenthoj, BY, Mackeprang, T, Svarer, C, Rasmussen, H, Pinborg, LH, Friberg, L, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 2006; 60: 621–9.
42 Tuppurainen, H, Kuikka, JT, Laakso, MP, Viinamäki, H, Husso, M, Tiihonen, J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 382–7.
43 Graff-Guerrero, A, Mizrahi, R, Agid, O, Marcon, H, Barsoum, P, Rusjan, P, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009; 34: 1078–86.
44 Kessler, RM, Woodward, ND, Riccardi, P, Li, R, Ansari, MS, Anderson, S, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009; 65: 1024–31.
45 Tuppurainen, H, Kuikka, J, Viinamäki, H, Husso-Saastamoinen, M, Bergström, K, Tiihonen, J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003; 8: 453–5.
46 Nozaki, S, Kato, M, Takano, H, Ito, H, Takahashi, H, Arakawa, R, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 2009; 108: 7884.
47 Lindström, LH, Gefvert, O, Hagberg, G, Lundberg, T, Bergström, M, Hartvig, P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681–8.
48 Elkashef, AM, Doudet, D, Bryant, T, Cohen, RM, Li, SH, Wyatt, RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000; 100: 111.
49 Kumakura, Y, Cumming, P, Vernaleken, I, Buchholz, H-G, Siessmeier, T, Heinz, A, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007; 27: 8080–7.
50 Okubo, Y, Suhara, T, Suzuki, K, Kobayashi, K, Inoue, O, Terasaki, O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634–6.
51 Karlsson, P, Farde, L, Halldin, C, Sedvall, G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761–7.
52 Abi-Dargham, A, Mawlawi, O, Lombardo, I, Gil, R, Martinez, D, Huang, Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708–19.
53 Arakawa, R, Ichimiya, T, Ito, H, Takano, A, Okumura, M, Takahashi, H, et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 2009; 43: 1219–23.
54 Guo, N, Hwang, D-R, Lo, E-S, Huang, Y-Y, Laruelle, M, Abi-Dargham, A. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 2003; 28: 1703–11.
55 Lidow, MS, Goldman-Rakic, PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994; 91: 4353–6.
56 Ekelund, J, Slifstein, M, Narendran, R, Guillin, O, Belani, H, Guo, N-N, et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 2007; 9: 117–25.
57 Hirvonen, J, Johansson, J, Teräs, M, Oikonen, V, Lumme, V, Virsu, P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 2008; 28: 1059–69.
58 Egerton, A, Demjaha, A, McGuire, P, Mehta, MA, Howes, OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50: 524–31.
59 Cropley, VL, Fujita, M, Bara-Jimenez, W, Brown, AK, Zhang, X-Y, Sangare, J, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008; 163: 171–82.
60 Rousset, OG, Ma, Y, Evans, AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904–11.
61 Kim, E, Shidahara, M, Tsoumpas, C, McGinnity, CJ, Kwon, JS, Howes, OD, et al. Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method. J Cereb Blood Flow Metab 2013; 33: 914–20.
62 Fornito, A, Yücel, M, Patti, J, Wood, SJ, Pantelis, C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res 2009; 108: 104–13.
63 Rousset, OG, Collins, DL, Rahmim, A, Wong, DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med 2008; 49: 1097–106.
64 Demjaha, A, Murray, RM, McGuire, PK, Kapur, S, Howes, OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203–10.
65 Egerton, A, Mehta, MA, Montgomery, AJ, Lappin, JM, Howes, OD, Reeves, SJ, et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33: 1109–32.
66 Abi-Dargham, A, Rodenhiser, J, Printz, D, Zea-Ponce, Y, Gil, R, Kegeles, LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104–9.
67 Kuwabara, H, McCaul, ME, Wand, GS, Earley, CJ, Allen, RP, Weerts, EM, et al. Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method. J Nucl Med 2012; 53: 805–12.
68 Hietala, J, Någren, K, Lehikoinen, P, Ruotsalainen, U, Syvälahti, E. Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 1999; 19: 210–7.
69 Narendran, R, Slifstein, M, Guillin, O, Hwang, Y, Hwang, D-R, Scher, E, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006; 60: 485–95.
70 Trikalinos, TA, Churchill, R, Ferri, M, Leucht, S, Tuunainen, A, Wahlbeck, K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004; 57: 1124–30.
71 Stang, A. Low P-values exclude nothing, and P-values are no substitute for measures of effect. J Clin Epidemiol 2011; 64: 452453; author reply 453.
72 Bose, SK, Turkheimer, FE, Howes, OD, Mehta, MA, Cunliffe, R, Stokes, PR, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 2008; 106: 148–55.
73 Howes, OD, Montgomery, AJ, Asselin, M-C, Murray, RM, Grasby, PM, McGuire, PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry 2007; 191 (suppl 51): s138.
74 Howes, OD, Egerton, A, Allan, V, McGuire, P, Stokes, P, Kapur, S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550–9.
75 Sánchez-González, MA, García-Cabezas, MA, Rico, B, Cavada, C. The primate thalamus is a key target for brain dopamine. J Neurosci 2005; 25: 6076–83.
76 Laruelle, M, Abi-Dargham, A, van Dyck, CH, Gil, R, D'Souza, CD, Erdos, J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235–40.
77 Breier, A, Su, TP, Saunders, R, Carson, RE, Kolachana, BS, de Bartolomeis, A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569–74.
78 Howes, OD, Montgomery, AJ, Asselin, M-C, Murray, RM, Valli, I, Tabraham, P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 1320.
79 Howes, O, Bose, S, Turkheimer, F, Valli, I, Egerton, A, Stahl, D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011; 16: 885–6.
80 Mizrahi, R, Addington, J, Rusjan, PM, Suridjan, I, Ng, A, Boileau, I, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012; 71: 561–7.
81 Howes, OD, Williams, M, Ibrahim, K, Leung, G, Egerton, A, McGuire, PK, et al. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 2013; 136: 3242–51.
82 Narendran, R, Mason, NS, May, MA, Chen, C-M, Kendro, S, Ridler, K, et al. Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [11C]FLB 457: reproducibility studies. Synapse 2011; 65: 3540.
83 Montgomery, AJ, Asselin, M-C, Farde, L, Grasby, PM. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab 2007; 27: 369–77.
84 Riccardi, P, Li, R, Ansari, MS, Zald, D, Park, S, Dawant, B, et al. Amphetamineinduced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006; 31: 1016–26.
85 Chou, YH, Halldin, C, Farde, L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse 2000; 38: 138–43.
86 Mukherjee, J, Christian, BT, Narayanan, TK, Shi, B, Collins, D. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 2005; 1032: 7784.
87 Slifstein, M, Narendran, R, Hwang, D-R, Sudo, Y, Talbot, PS, Huang, Y, et al. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus constant infusion studies. Synapse 2004; 54: 4663.
88 Aalto, S, Brück, A, Laine, M, Någren, K, Rinne, JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005; 25: 2471–7.
89 Okauchi, T, Suhara, T, Maeda, J, Kawabe, K, Obayashi, S, Suzuki, K. Effect of endogenous dopamine on endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET. Synapse 2001; 41: 8795.
90 Tsukada, H, Harada, N, Nishiyama, S, Fukumoto, D, Kakiuchi, T. Acute NMDA receptor antagonism induces biphasic striatal utilization of L-[beta-11C]DOPA: PET studies in the conscious monkey brain. Synapse 2005; 57: 116–9.
91 Cropley, VL, Innis, RB, Nathan, PJ, Brown, AK, Sangare, JL, Lerner, A, et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 2008; 62: 399408.
92 Frankle, WG, Mason, NS, Rabiner, EA, Ridler, K, May, MA, Asmonga, D, et al. No effect of dopamine depletion on the binding of the high-affinity D 2/3 radiotracer [11C]FLB 457 in the human cortex. Synapse 2010; 64: 879–85.
93 Stone, JM, Howes, OD, Egerton, A, Kambeitz, J, Allen, P, Lythgoe, DJ, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 2010; 68: 599602.
94 Blasi, G, Napolitano, F, Ursini, G, Taurisano, P, Romano, R, Caforio, G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108: 1158–63.

Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies

  • Joseph Kambeitz (a1), Anissa Abi-Dargham (a2), Shitij Kapur (a1) and Oliver D. Howes (a3)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies

  • Joseph Kambeitz (a1), Anissa Abi-Dargham (a2), Shitij Kapur (a1) and Oliver D. Howes (a3)
Submit a response


Arn't we scraping the barrel now?

Prasanna N. de Silva, Consultant Old Age Psychiatrist
13 June 2014

Kambeitz and colleagues (1) have found no meaningful evidence of frontal hypodoperminergia in their well designed meta-analysis. This is embarrassing, as the current version of the Dopamine Hypothesis rests on reduced dopamine distribution to the Frontal lobe, with excess dopamine input to sub cortical (striatal and mesolimbic) areas. Certainly there is no evidence for the original Dopamine hypothesis of excess Dopamine production in the brain, which was assumed from the effectiveness of dopamine blockers in treating so called positive symptoms.

Should we now break out of this mental construct, and look at other possibilities of reduced frontal metabolism? This could be either due to neuronal membrane problems like brain GLUT (glucose transporter) deficits (2) or intra neuronal problems in the metabolic pathway (3) either within or out with mitochondria. In both these situations, pathology would be both neurodevelopmental and neurodegenerative in nature, thereby releasingus out of that dichotomy as well.

Perhaps the variation of metabolism seen within the cortex (suggestedby reduced perfusion and glucose uptake) might be the result of each humanusing different parts of the brain (or different circuits)due to their preferred activity or talents. Therefore unlike dementia where the advice is 'use it or lose it', pathophysiology in schizophrenia could be based onthe idea of 'use it and lose it'

The search for alternative constructs to explain schizophrenia has been given extra impetus by the accumulating evidence of dose related cortical thinning over time in patients using dopamine blockers (4), including the atypical drugs currently in vogue.

An alternative paradigm might just release us to look for non dopaminergic treatments. There is the other issue of what exactly we tell patients and carers about aetiology and pathogenesis following this negative result coupled with the finding of progressive cortical thinning caused by our drugs.

References1.Kambeitz, J., Abi-Dargham, A., Kapur, S., and Howes, O. Alterations in cortical and extra striatal sub cortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. TheBritish Journal of Psychiatry 2014 Vol 204 pp 420-4292.McDermott E., de Silva P.N. Impaired neuronal glucose uptake in pathogenesis of schizophrenia - can GLUT 1 and GLUT 3 deficits explain imaging, post mortem and pharmacological findings? Medical Hypothesis, 2005 Vol 65, pp 1076 -1081, 20053.Girgis, R.R., Javich, J.A., Lieberman, J.A. (2008) Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effectsand insulin signalling pathway. Molecular Psychiatry 2008 Vol 8, pp 1-124.Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia. Arch Gen Psychiatry 2011 Feb;68(2):128-37

... More

Conflict of interest: None declared

Write a reply


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *